BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19787625)

  • 1. Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis.
    Zancan M; Galdi F; Di Tonno F; Mazzariol C; Orlando C; Malentacchi F; Agostini M; Maran M; Del Bianco P; Fabricio AS; Murer B; Pianon C; Gion M
    Int J Biol Markers; 2009; 24(3):147-55. PubMed ID: 19787625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.
    Casadio V; Calistri D; Tebaldi M; Bravaccini S; Gunelli R; Martorana G; Bertaccini A; Serra L; Scarpi E; Amadori D; Silvestrini R; Zoli W
    Urol Oncol; 2013 Nov; 31(8):1744-50. PubMed ID: 23141783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free DNA in urine: a new marker for bladder cancer? Preliminary data.
    Zancan M; Franceschini R; Mimmo C; Vianello M; Di Tonno F; Mazzariol C; Malossini G; Gion M
    Int J Biol Markers; 2005; 20(2):134-6. PubMed ID: 16011045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary cell-free DNA as a potential tumor marker for bladder cancer.
    Chang HW; Tsui KH; Shen LC; Huang HW; Wang SN; Chang PL
    Int J Biol Markers; 2007; 22(4):287-94. PubMed ID: 18161660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer.
    Brisuda A; Pazourkova E; Soukup V; Horinek A; Hrbáček J; Capoun O; Svobodova I; Pospisilova S; Korabecna M; Mares J; Hanuš T; Babjuk M
    Urol Int; 2016; 96(1):25-31. PubMed ID: 26338254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.
    Salvi S; Gurioli G; Martignano F; Foca F; Gunelli R; Cicchetti G; De Giorgi U; Zoli W; Calistri D; Casadio V
    Dis Markers; 2015; 2015():574120. PubMed ID: 26412928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.
    Casadio V; Calistri D; Salvi S; Gunelli R; Carretta E; Amadori D; Silvestrini R; Zoli W
    Biomed Res Int; 2013; 2013():270457. PubMed ID: 23509700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
    Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
    Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free DNA Integrity Analysis in Urine Samples.
    Casadio V; Salvi S; Martignano F; Gunelli R; Ravaioli S; Calistri D
    J Vis Exp; 2017 Jan; (119):. PubMed ID: 28117781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer.
    Mutlu N; Turkeri L; Emerk K
    Clin Chem Lab Med; 2003 Aug; 41(8):1069-74. PubMed ID: 12964816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
    Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
    Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
    BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer.
    Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; García J; Alférez F; González deBuitrago JM; Navajo JA
    Urology; 2000 Apr; 55(4):526-32. PubMed ID: 10736496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
    BJU Int; 1999 Oct; 84(6):706-13. PubMed ID: 10510120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
    Mungan NA; Vriesema JL; Thomas CM; Kiemeney LA; Witjes JA
    Urology; 2000 Nov; 56(5):787-92. PubMed ID: 11068302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.